European Primary Care Cardiovascular Society

Hypertension - Can we agree on diagnostic and therapeutic thresholds?

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Prof. Richard McManus, prof. Richard Hobbs and prof. Christos Lionis

Complexities of managing heart failure

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Lipids and food

July 11, 2018 - Prof. David Marais - Cape Town, South Africa

The cardiovascular challenge for primary care in diabetes

July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Spain - EPCCS Introduction

June 19, 2018

Lower Extremity Artery Disease: a neglected major CV disease: Diagnosis and clinical management in primary care

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Rafel Ramos (Girona, Spain)

Lipid lowering: the evidence, the guidelines, the clinical reality

Mar. 17, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Monika Hollander, prof. Frank Visseren, dr. Jan Oltrogge

Management of CV risk that comes with T2DM in light of novel treatment options

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Pharmacist intervention in American 'black barbershops' effective at lowering BP

Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

Striking results for weight reduction in T2DM in primary care based program

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 20, 2017 - AHA 2017 - Anaheim, CA, USA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

Good BP measurement depends more on appropriate technique than on absence of staff

Nov. 25, 2017 - AHA 2017 - Anaheim, CA, USA - Prof Karen Johnson - Memphis, TN, VS

Things to consider when aiming to prevent stroke in a patient with AF

May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

What can be learned from the latest hypertension trials?

May 26, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

May 25, 2017

How do the latest guideline changes affect management of dyslipidaemia in primary care?

May 26, 2017

Comparable HbA1c reduction with intermittent and continuous restricted diet in obese diabetic patients

Aug. 16, 2018 - Carter S et al. - JAMA Network Open 2018

A randomized, non-inferiority trial showed comparable HbA1c reductions with an intermittent energy restricted diet compared to a continuous energy restricted diet in adult overweight and obese T2DM patients.

Hypertension - Can we agree on diagnostic and therapeutic thresholds?

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Prof. Richard McManus, prof. Richard Hobbs and prof. Christos Lionis
Three professors discuss how best to measure blood pressure, when to call it hypertension, and once hypertension is diagnosed, what BP target to aim for, based on the latest scientific insights.

EPCCS 2018 Three professors discuss how best to measure blood pressure, when to call it hypertension, and once hypertension is diagnosed, what BP target to aim for, based on the latest scientific insights.

Association between physical activity and reduced risk of diabetes at high CVD risk

Aug. 13, 2018 - Kraus WE et al. - BMJ Open Diab Res Care 2018

A subanalysis of the NAVIGATOR-trial showed a significant association between physical activity and reduced risk of the development of diabetes in patients at high CVD risk, independent of gender.

Insufficient ground for adding non-traditional risk factors to CVD risk assessment

Aug. 3, 2018 - news

The US Preventive Services Task Force (USPSTF) found evidence that adding the non-traditional risk factors ABI, hsCRP and CAC could slightly improve current CVD risk assessment, but the clinical meaning is unknown.

Substantial variation of time to benefit between cholesterol-lowering agents

Aug. 3, 2018 - Barter PJ, Waters DD. - J Clin Lipidol. 2018

An explorative study compared the timepoint at which outcome curves separate among 17 statin and 7 non-statin trials. Results suggest that futility should not be declared too early in trials.

Effects antihypertensive and lipid-lowering therapy on CV risk not influenced by lifestyle

Aug. 2, 2018 - Dagenais GR, et al. - J Am Heart Assoc. 2018

A post hoc analysis of a randomized trial showed reduced CVD risk after rosuvastatin therapy with and without candestartan/hydrochlorothiazide, regardless of the number of healthy lifestyle factors.

Update: recommendations sports-participation in CAD patients-athletes

Aug. 1, 2018 - news

The Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC) has updated its recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease.

Increased intake omega-3 fatty acids: little or no effects on CV prevention

Aug. 1, 2018 - news

A Cochrane meta-analysis suggests little or no effect of increased intake (dietary or supplementation) of the omega-3 fatty acids ALA and LCn3 on CVD and mortality in adults.

Meeting Impression | Preventing CVD in Patients with T2DM

May 3, 2018 - Ljubljana, Slovenia
May 3, 2018 - Ljubljana, Slovenia

Download the meeting impression of this PACE symposium during EuroPrevent 2018, that considered how to apply novel outcome data with GLP-1 RA to clinical practice.

Summary | Practical management of cardiovascular risk: Lessons from latest diabetes trials

May 3, 2018 – Prof. Lars Rydén, MD

This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Summary | Diabetes: How to reduce risk from a cardiovascular perspective?

May 3, 2018 – Prof. Diederick Grobbee, MD

This is a summary of presentation given by prof. Grobbee, in which he discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.

Summary | The cardiovascular challenge for primary care in diabetes

May 3, 2018 – Prof. Richard Hobbs, MD

This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.